---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-002295"
form_type: "8-K"
ticker: "KPRX"
cik: "0001372514"
company_name: "KIORA PHARMACEUTICALS INC"
filed_at: "2023-01-09T23:59:59+00:00"
generated_at: "2026-06-20T17:37:20.836597+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Kiora updates pipeline; KIO-301 Phase 1b results expected 1H 2023

## Summary
- KIO-301 (RP) Phase 1b ABACUS trial first patient dosed Q4 2022; preliminary results expected 1H 2023.
- KIO-101 (OPRA+) Phase 2 trial conditionally approved; first patient enrollment planned 1H 2023.
- KIO-201 (PCED) Phase 2 trial fully enrolled Q4 2022; results and FDA registration dialogue expected 1H 2023.
- Raised ~$20M gross in past 18 months; received $1.2M in R&D tax credits.
- Appointed Melissa Tosca as EVP Finance; strengthened SEC reporting procedures.

## SEC filing metadata
- accession: 0001104659-23-002295
- form_type: 8-K
- ticker: KPRX
- cik: 0001372514
- company_name: KIORA PHARMACEUTICALS INC
- filed_at: 2023-01-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1372514/000110465923002295/0001104659-23-002295-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1372514/000110465923002295/tm232667d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-002295
- JSON: https://secwatch.observer/filing/0001104659-23-002295.json
- Plain text: https://secwatch.observer/filing/0001104659-23-002295.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.